The Consortium for the Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR), supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), was established in 2000 to provide a resource for the scientific community to explore genetic and non-genetic factors affecting rheumatoid arthritis (RA) occurrence and outcomes in African Americans. The long term objective is a database and a repository of 1,100 RA and 550 matched healthy African-American subjects.
This consortium is a collaborative effort among five academic institutions:
University of Alabama at Birmingham, Birmingham, AL (Coordinating Center)
Grady Hospital/Emory University, Atlanta, GA
University of North Carolina, Chapel Hill, NC
Medical University of South Carolina, SC
Washington University, St. Louis, MO
This CLEAR registry has two arms: a longitudinal arm for subjects with early RA (enrollment from 2000 to 2005) and a cross-sectional arm for subjects with any disease duration (enrollment began in 2006 and is ongoing). CLEAR has two components: a database and a repository. The database contains extensive demographic, socioeconomic, clinical and radiographic information. The repository contains genomic DNA, RNA from peripheral blood cells, plasma and serum. These resources allow a comprehensive analysis of factors influencing disease susceptibility and severity in African-Americans with RA.
CLEAR I is composed of African-American RA patients with early disease (< 2 years) who are followed longitudinally until 5 years of disease duration. CLEAR II is a cross sectional arm, in which patients with any disease duration (typically longstanding) are seen at one time point.
For additional details about CLEAR I and CLEAR II RA patients, as well as control subjects and, available data and samples, click here.
For a list of publications resulting from studies utilizing CLEAR data and samples, click here.
- Last Updated on March 18, 2013